Reported 1 day ago
In light of President Trump's proposed tariffs aimed at encouraging biopharma manufacturing in the U.S., Jefferies' Michael Yee highlights Vertex, Amgen, and Gilead as top biotech stocks that are less affected due to their limited overseas production. He notes these companies have performed well year-to-date, and while some sector concerns exist, they remain strong defensive investments.
Source: YAHOO